Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Research Officer

General Counsel and Secretary

President and CEO

Chief Financial Officer

VP & Corporate Controller

Chief Scientific Officer

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunoth...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-30	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-26	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-23	Premium	sold	Premium	Premium	Premium	Chief Research Officer
2024-01-22	Premium	sold	Premium	Premium	Premium	General Counsel and Secretary
2024-01-22	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-22	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-20	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-20	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-20	Premium	acquired	Premium	Premium	Premium	Chief Research Officer
2024-01-20	Premium	acquired	Premium	Premium	Premium	General Counsel and Secretary
2024-01-20	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-11-03	Premium	sold	Premium	Premium	Premium	President and CEO
2023-11-03	Premium	sold	Premium	Premium	Premium	General Counsel and Secretary
2023-11-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-11-02	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-11-02	Premium	acquired	Premium	Premium	Premium	General Counsel and Secretary
2023-08-31	Premium	acquired	Premium	Premium	Premium	Chief Research Officer
2023-08-31	Premium	acquired	Premium	Premium	Premium	General Counsel and Secretary
2023-08-31	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-08-18	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-08-18	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-06-08	Premium	sold	Premium	Premium	Premium	General Counsel and Secretary
2023-06-07	Premium	acquired	Premium	Premium	Premium	General Counsel and Secretary
2023-06-07	Premium	acquired	Premium	Premium	Premium	Chief Research Officer
2023-06-07	Premium	acquired	Premium	Premium	Premium	VP & Corporate Controller

DTIL - Precision BioSciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for DTIL